Results 61 to 70 of about 4,014 (178)

Profile of sofosbuvir/velpatasvir/voxilaprevir in the treatment of hepatitis C

Infection and Drug Resistance, 2019
Lindsey M Childs-Kean, Natalie A Brumwell, Emma F LodlDepartment of Pharmacotherapy and Translational Research, University of Florida College of Pharmacy, Gainesville, FL, USAAbstract: The treatment of chronic hepatitis C has been revolutionized with the
Childs-Kean LM, Brumwell NA, Lodl EF
doaj  

HCV‐Specific T‐Cell Recovery After a Year of SVR Following DAA Therapy

Journal of Medical Virology, Volume 98, Issue 8, August 2026.
ABSTRACT Direct‐acting antiviral (DAA) drugs lead to sustained virologic response (SVR) in almost all treated patients with chronic hepatitis C virus (HCV) infection. Despite this success, the long‐term effects of HCV clearance by DAA therapy on T‐cell‐mediated antiviral immunity remain unclear, particularly concerning the restoration of immune ...
Tetiana Pozniak, Salma Sharaf, Chloe Gross, Emade Ebah, Arshi Khanam, Amelia Cover, Ashley Davis, Shyam Kottilil, Poonam Mathur, Alip Ghosh   +9 more
wiley   +1 more source

Potential interactions between pangenotypic direct-acting antivirals and concomitant cardiovascular therapies in patients with chronic hepatitis C virus infection

Journal of International Medical Research, 2020
Objective To identify potential drug interactions (DIs) between pangenotypic direct-acting antivirals (pDAAs) and concomitant cardiovascular (CV) therapies in patients with chronic hepatitis C (CHC).
Antoni Sicras-Mainar, Ramón Morillo-Verdugo   +1 more
doaj   +1 more source

Differing Epidemiology of Chronic Hepatitis C Infection, Treatment, and Outcomes Among Migrants and Australian‐Born Patients

Journal of Viral Hepatitis, Volume 33, Issue 8, August 2026.
ABSTRACT The burden of hepatitis C virus (HCV) infection often falls disproportionately on migrant populations within high‐income countries. Differences in health literacy, language, comorbidities, and HCV genotype may influence HCV natural history. 3537 persons including 652 migrants treated for HCV infection with direct‐acting antiviral (DAA) (2016 ...
Belaynew W. Taye, Patricia C. Valery, Simone I. Strasser, Martin Weltman, Alex J. Thompson, Miriam T. Levy, Barbara Leggett, Amany Zekry, Y. Julian Rong, Marie Sinclair, Jacob George, William Sievert, Gerry MacQuillan, Edmund Tse, Amanda Wade, Wendy Cheng, Stuart K. Roberts, Paul J. Clark   +17 more
wiley   +1 more source

Sofosbuvir plus velpatasvir combination therapy for treatment- Experienced patients with genotype 1 or 3 hepatitis c virus infection

, 2015
Background: Effective treatment options are needed for patients with genotype 1 or 3 hepatitis C virus (HCV) infection in whom previous therapy has failed.
Gane, EJ, Strasser, SI, Han, L, McHutchison, JG, Rabinovitz, M, Flamm, SL, Rajender Reddy, K, Pianko, S, Shiffman, ML, Towner, WJ, Kumar, S, Dore, GJ ; https://orcid.org/, Mogalian, E, Roberts, SK, Doehle, B, Stedman, CAM, McNally, J, Brainard, DM   +17 more
core   +1 more source

Improving access to direct acting antivirals via a multimodal integrated care program in an addiction medicine clinic

The American Journal on Addictions, Volume 35, Issue 4, Page 534-542, July 2026.
Abstract Background and Objectives Injection drug use is a driver of hepatitis C virus (HCV) transmission, thus integrating HCV care into addiction care is likely necessary for HCV elimination. Here we describe how we integrated HCV care into our addiction medicine (AM) clinic and evaluate its effect on HCV treatment.
Arya Zandvakili, Joseph Rattenni, James Burton, Lakshmi Guduguntla, Marcus Osman, Sayeh Sabbagh, Stephan Arndt, Ben Miskle, Quanhathai Kaewpoowat, Michael Ohl, Andrea Weber, Alison Lynch   +11 more
wiley   +1 more source

Real-World Clinical Application of 12-Week Sofosbuvir/Velpatasvir Treatment for Decompensated Cirrhotic Patients with Genotype 1 and 2: A Prospective, Multicenter Study

Infectious Diseases and Therapy, 2020
Introduction Clinical trials of direct-acting antivirals for patients with decompensated cirrhosis have been conducted, but there is limited information on the medicinal applications in clinical settings.
Masanori Atsukawa, Akihito Tsubota, Chisa Kondo, Hidenori Toyoda, Makoto Nakamuta, Koichi Takaguchi, Tsunamasa Watanabe, Atsushi Hiraoka, Haruki Uojima, Toru Ishikawa, Motoh Iwasa, Toshifumi Tada, Akito Nozaki, Makoto Chuma, Shinya Fukunishi, Akira Asai, Toru Asano, Chikara Ogawa, Hiroshi Abe, Naoki Hotta, Toshihide Shima, Etsuko Iio, Shigeru Mikami, Yoshihiko Tachi, Shinichi Fujioka, Hironao Okubo, Noritomo Shimada, Joji Tani, Isao Hidaka, Akio Moriya, Kunihiko Tsuji, Takehiro Akahane, Naoki Yamashita, Tomomi Okubo, Taeang Arai, Kiyoshi Morita, Kazuhito Kawata, Yasuhito Tanaka, Takeshi Okanoue, Shin Maeda, Takashi Kumada, Katsuhiko Iwakiri, KTK49 Liver Study Group   +42 more
doaj   +1 more source

Discovery of SARS-CoV-2 antiviral synergy between remdesivir and approved drugs in human lung cells

Scientific Reports, 2022
SARS coronavirus 2 (SARS-CoV-2) has caused an ongoing global pandemic with significant mortality and morbidity. At this time, the only FDA-approved therapeutic for COVID-19 is remdesivir, a broad-spectrum antiviral nucleoside analog.
Xammy Huu Wrynla, Eddie Wehri, Erik Van Dis, Scott B. Biering, Livia H. Yamashiro, Chi Zhu, Julien Stroumza, Claire Dugast-Darzacq, Thomas G. W. Graham, Xuanting Wang, Steffen Jockusch, Chuanjuan Tao, Minchen Chien, Wei Xie, Dinshaw J. Patel, Cindy Meyer, Aitor Garzia, Thomas Tuschl, James J. Russo, Jingyue Ju, Anders M. Näär, Sarah Stanley, Julia Schaletzky   +22 more
doaj   +1 more source

Repurposed Medicines for Viruses With Epidemic or Pandemic Potential: A Horizon Scan

Pharmacology Research &Perspectives, Volume 14, Issue 3, June 2026.
ABSTRACT Viruses such as Ebola, Marburg, influenza, mpox, MERS‐CoV, SARS‐CoV, and SARS‐CoV‐2 may be considered pathogens of epidemic or pandemic concern. Developing novel antiviral medicines can be time‐consuming and resource intensive. Repurposing existing medicines with known or potential antiviral activity offers a faster, cost‐effective strategy to
Sola Akinbolade, Rhiannon Potter, Alex Inskip, Jane Nesworthy, Kirsti Brock, Gill Norman   +5 more
wiley   +1 more source

Sofosbuvir–velpatasvir–voxilaprevir for treating chronic hepatitis C

, 2018
To appraise the clinical and cost effectiveness of sofosbuvir velpatasvir voxilaprevir within its marketing authorisation for treating chronic hepatitis ...
Onyimadu, Oluchukwu, Harris, Petra, Kalita, Neelam, Cooper, Keith, Picot, Joanna   +4 more
core   +1 more source